Mar 10, 2021 / 03:55PM GMT
Travis Steed -
Good morning, everybody. This is Travis Steed. I'm the Medical Device Analyst at Barclays. And up next, we have Axonics. Very pleased to welcome Ray Cohen, CEO; Dearen, President and CFO; and then Neil Bhalodkar, Head of Investor Relations. Welcome, and thanks, and hopefully, next year we'll be in person in Miami, but for now, we'll do this virtually over Zoom.
Raymond W. Cohen - Axonics Modulation Technologies, Inc. - CEO & Director
Thanks for having us.
Danny L. Dearen - Axonics Modulation Technologies, Inc. - President & CFO
Thanks for inviting us.
Questions and Answers:
Travis Steed -Of course. So Ray, I just wanted to start out, the recent acquisition that you did with Bulkamid, usually, single product companies at the beginning of their growth opportunity, make a sizable acquisition in adjacent area. So just wanted to start off give some overview of like Bulkamid, why that product then and why now?
Raymond W. Cohen - Axonics